Perspective Therapeutics/$CATX

Perspective Therapeutics shares fall amid continued selling pressure and an overhang from Lantheus’s disclosed plans to dispose of its 10% stake.
5 hours agoLightyear AI
1D1W1MYTD1Y5YMAX

About Perspective Therapeutics

Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Ticker
$CATX
Sector
Health
Primary listing
AMEX
Employees
165
Headquarters
Seattle, United States
Website
www.perspectivetherapeutics.com

CATX Metrics

BasicAdvanced
$333M
-
-$1.25
1.80
-

What the Analysts think about CATX

Analyst ratings (Buy, Hold, Sell) for Perspective Therapeutics stock.
Analyst projections of the future price of Perspective Therapeutics stock.

Bulls say / Bears say

Perspective’s lead VMT-α-NET programme produced an investigator-assessed response in 10 of 23 patients in its 5.0 mCi Cohort 2, or 43%, with responses continuing to deepen. The signal supports the company’s plan to prepare a Phase 3 study in neuroendocrine tumours. (GlobeNewswire, Perspective Therapeutics)
The pipeline offers more than one route to success. In heavily pre-treated melanoma, VMT01 produced two partial responses among seven 3.0 mCi monotherapy patients, while six had stable disease or a partial response and no dose-limiting toxicities were reported. (GlobeNewswire, Perspective Therapeutics)
Perspective reported $237 million of cash, cash equivalents and short-term investments at 30 June 2026, and says this should fund planned milestones and operational investment into late 2027. Its expanding regional manufacturing network is intended to support both the planned Phase 3 study and potential commercial supply. (Perspective Therapeutics)
The lead programme is still in Phase 1/2a, and key efficacy data from the remaining patients in Cohort 2 and from newer cohorts are pending. Phase 3 site activation is only targeted for around year-end 2026 and remains dependent on regulatory feedback and protocol finalisation. (Perspective Therapeutics, GlobeNewswire)
VMT01’s melanoma evidence remains thin: the headline result is two partial responses in only seven monotherapy patients. That small, early, heavily pre-treated sample may not predict durable benefit in a larger or controlled study. (GlobeNewswire, Perspective Therapeutics)
The company raised about $164 million net in a February 2026 offering, yet cash and short-term investments fell from about $271 million at 31 March to $237 million at 30 June. With major clinical and manufacturing spending continuing through 2027, further fundraising and shareholder dilution remain possible. (GlobeNewswire, Perspective Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.

CATX Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

CATX Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing CATX

Funds
Fund name
Fund size
$CATX weighting
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.